HUB Organoids

Executive Summary

HUB Organoids is a Dutch biotech company pioneering patient-derived organoid technology to predict drug responses in the lab, bridging the gap between preclinical models and clinical outcomes. Founded in 2013 and headquartered in Utrecht, the company's patented platform generates 'mini-organs in a dish' from both healthy and diseased tissues, enabling more accurate drug screening and personalized treatment selection. Its technology holds promise for accelerating drug discovery, reducing late-stage failures, and advancing precision medicine across therapeutic areas such as oncology and gastrointestinal diseases. As a pre-clinical stage private company, HUB Organoids is positioned to partner with pharmaceutical firms and academic institutions to validate its organoid models for regulatory and clinical use. The company's innovative approach could significantly impact the drug development pipeline by providing a more physiologically relevant human model than traditional cell lines or animal testing.

Upcoming Catalysts (preview)

• H2 2026Strategic partnership with large pharma for organoid-based drug screening60% success
• 2026Series B or Series C funding round to scale operations70% success
• Q3 2026Publication of key validation data in peer-reviewed journal50% success